TOTAL VOLUME:
$134b
24H VOL:
$103,397,351
24H TRANSACTIONS:
2,388,728,490
OPEN INTEREST:
$1,410,176,180
399,592
Markets across
30,097
events
MATCHED EVENTS:
2,622
PLATFORM COVERAGE:
5
Polymarket:
39%
VS.
Kalshi:
61%
Closed: Jul 30, 8:52 AM EST
Polymarket
As of market creation, Labcorp is estimated to release earnings on July 30, 2026. The Street consensus estimate for Labcorp’s non-GAAP EPS for the relevant quarter is $4.77 as of market creation. This market will resolve to "Yes" if Labcorp reports non-GAAP EPS greater than $4.77 for the relevant quarter in its next quarterly earnings release. Otherwise, it will resolve to "No." The resolution source will be the non-GAAP EPS listed in the company’s official earnings documents. If Labcorp releases earnings without non-GAAP EPS, then the market will resolve according to the non-GAAP EPS figure reported by SeekingAlpha. If no such figure is published within 96h of market close (4:00:00pm ET) on the day earnings are announced, the market will resolve according to the GAAP EPS listed in the company’s official earnings documents; or, if not published there, according to the GAAP EPS provided by SeekingAlpha. If no GAAP EPS number is available from either source at that time, the market will resolve to “No.” (For the purposes of this market, GAAP EPS refers to diluted GAAP EPS, unless it is not published, in which case it refers to basic GAAP EPS.) If the company does not release earnings within 45 calendar days of the estimated earnings date, this market will resolve to “No.” Note: Subsequent restatements, corrections, or revisions made to the initially announced non-GAAP EPS figure will not qualify for resolution, except in the case of obvious and immediate mistakes (e.g., fat finger errors, as with Lyft's (LYFT) earnings release in February 2024). Note: The strike prices used in these markets are derived from SeekingAlpha estimates, and reflect the consensus of sell-side analyst estimates for non-GAAP EPS. Note: All figures will be rounded to the nearest cent using standard rounding. Note: For the purposes of this market, IFRS EPS will be treated as GAAP EPS. Note: If multiple versions of non-GAAP EPS are published, the market will resolve according to the primary headline non-GAAP EPS number, which is typically presented on a diluted basis. If diluted is not published, then basic non-GAAP EPS will qualify. Note: All figures are expressed in USD, unless otherwise indicated. Note: For primarily internationally listed companies, this market refers specifically to the shares traded in the United States on U.S. stock exchanges such as the NYSE or Nasdaq. In cases where the company trades in the U.S. through an American Depositary Receipt (ADR) or American Depositary Share (ADS), this market will refer to the ADR/ADS.
As of market creation, Labcorp is estimated to release earnings on July 30, 2026. The Street consensus estimate for Labcorp’s non-GAAP EPS for the relevant quarter is $4.77 as of market creation. This market will resolve to "Yes" if Labcorp reports non-GAAP EPS greater than $4.77 for the relevant quarter in its next quarterly earnings release. Otherwise, it will resolve to "No." The resolution source will be the non-GAAP EPS listed in the company’s official earnings documents. If Labcorp releases earnings without non-GAAP EPS, then the market will resolve according to the non-GAAP EPS figure reported by SeekingAlpha. If no such figure is published within 96h of market close (4:00:00pm ET) on the day earnings are announced, the market will resolve according to the GAAP EPS listed in the company’s official earnings documents; or, if not published there, according to the GAAP EPS provided by SeekingAlpha. If no GAAP EPS number is available from either source at that time, the market will resolve to “No.” (For the purposes of this market, GAAP EPS refers to diluted GAAP EPS, unless it is not published, in which case it refers to basic GAAP EPS.) If the company does not release earnings within 45 calendar days of the estimated earnings date, this market will resolve to “No.” Note: Subsequent restatements, corrections, or revisions made to the initially announced non-GAAP EPS figure will not qualify for resolution, except in the case of obvious and immediate mistakes (e.g., fat finger errors, as with Lyft's (LYFT) earnings release in February 2024). Note: The strike prices used in these markets are derived from SeekingAlpha estimates, and reflect the consensus of sell-side analyst estimates for non-GAAP EPS. Note: All figures will be rounded to the nearest cent using standard rounding. Note: For the purposes of this market, IFRS EPS will be treated as GAAP EPS. Note: If multiple versions of non-GAAP EPS are published, the market will resolve according to the primary headline non-GAAP EPS number, which is typically presented on a diluted basis. If diluted is not published, then basic non-GAAP EPS will qualify. Note: All figures are expressed in USD, unless otherwise indicated. Note: For primarily internationally listed companies, this market refers specifically to the shares traded in the United States on U.S. stock exchanges such as the NYSE or Nasdaq. In cases where the company trades in the U.S. through an American Depositary Receipt (ADR) or American Depositary Share (ADS), this market will refer to the ADR/ADS.
Prediction market odds and traditional analyst forecasts often diverge because they measure different things. Analysts typically publish point estimates and ranges for earnings metrics, while this market aggregates trader beliefs into a single probability. Markets can react faster to breaking news and incorporate real-time sentiment, whereas analyst consensus updates lag. However, both sources aim to predict the same underlying event: whether Labcorp's actual results will exceed expectations. Comparing the two can reveal where professional forecasters and market participants disagree, sometimes highlighting overlooked risks or opportunities.
On Polymarket, this market is priced through an automated market maker that converts trader activity into real-time odds. On Polymarket, prices reflect that venue's order book, liquidity, and how traders price the outcome right now. Shares representing each outcome trade continuously, and the current price reflects the probability implied by recent buy and sell orders. As more traders bet on Labcorp beating earnings, the price of that outcome rises; conversely, skepticism pushes it lower. The spread between bid and ask prices narrows or widens based on trading volume and conviction, making it easy to see where the market consensus stands at any moment.
This market resolves around Jul 30, 2026, once Labcorp's quarterly earnings announcement is public and verified. The outcome is determined by comparing the company's reported earnings per share and revenue to the consensus estimates that were in effect at the time the market was created. If actual results exceed those benchmarks, the market resolves to a yes outcome; otherwise, it resolves to no. Resolution is confirmed once the earnings data is verifiable from credible public reporting and financial news sources.
Several catalysts can shift odds in this market before resolution. Labcorp's pre-earnings guidance, changes to analyst estimates, and broader healthcare or diagnostic industry trends all influence trader sentiment. Macroeconomic data affecting healthcare spending, competitor earnings surprises, and regulatory announcements can also sway the forecast. Additionally, any company-specific news—such as management commentary, clinical trial results, or contract wins—may prompt repricing. As the earnings date approaches, trading volume typically increases and volatility can spike, especially if new information emerges that challenges or reinforces the current market consensus.